Save
Email
Print
ShareJune 8, 2009 — Pulmonary hypertension is an unremitting disease caused by a progressive increase in blood pressure in the blood vessels of the lung; it leads to heart failure and ultimately death. Currently there are limited treatment options. However, You-Yang Zhao and colleagues, at the University of Illinois College of Medicine, Chicago, have identified in mice a new molecular pathway underlying pulmonary hypertension that they hope might provide novel therapeutic targets.
In the study, mice lacking either caveolin 1, eNOS, or both proteins were used to determine that chronic eNOS activation, secondary to loss of caveolin-1, can lead to pulmonary hypertension. Further analysis revealed that the chronic eNOS activation that induced pulmonary hypertension was associated with impaired activity of the protein PKG because it was modified by a process known as nitration.
As lung tissue from patients with a form of pulmonary hypertension known as idiopathic pulmonary arterial hypertension exhibited evidence of increased eNOS activation and PKG nitration and reduced caveolin-1 expression, the authors suggest that preventing and/or reversing PKG nitration might be of benefit to individuals with idiopathic pulmonary arterial hypertension.
Other social bookmarking and sharing tools:
Story Source:
The above story is reprinted from materials provided by Journal of Clinical Investigation, via EurekAlert!, a service of AAAS.
Note: Materials may be edited for content and length. For further information, please contact the source cited above.
Journal Reference:
- Persistent eNOS activation secondary to caveolin-1 deficiency induces pulmonary hypertension in mice and humans through PKG nitration. Journal of Clinical Investigation, June 1, 2009
Note: If no author is given, the source is cited instead.
more 
